Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exelixis, Inc.

< Previous 1 2 3 4 Next >
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Advances Board Refreshment Plan
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Reiterates Commitment to Shareholder Value Creation
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces $550 Million Share Repurchase Program
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.